| abstract |
Disclosed is an effective HCV vaccine composition, which is developed as a result of the finding of an optimum combination of an HCV antigen capable of inducing an antibody having an inhibitory activity on the infection by an HCV and an adjuvant.nSpecifically disclosed is a hepatitis C virus vaccine composition which comprises: inactivated virus particles produced by inactivating infectious hepatitis C virus particles that are produced from hepatitis C virus genome containing sequences respectively encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein derived from hepatitis C virus strain JFH1; a non-methylated CpG-containing oligonucleotide represented by SEQ ID NO:5 shown in the Sequence Listing; and aluminum hydroxide. |